Q2 2026 saw robust order intake and sales growth, driven by AI, medtech, and defense demand, with strong performance across all regions. Supply chain constraints and price increases persist, but margin guidance is maintained and further M&A is planned.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.